Asset Details
Do you wish to reserve the book?
Do publicly supported generic pharmacies improve financial risk protection? Findings from a nationally representative cross-sectional survey in India
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Do publicly supported generic pharmacies improve financial risk protection? Findings from a nationally representative cross-sectional survey in India
Do you wish to request the book?
Do publicly supported generic pharmacies improve financial risk protection? Findings from a nationally representative cross-sectional survey in India
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Do publicly supported generic pharmacies improve financial risk protection? Findings from a nationally representative cross-sectional survey in India
2026
Overview
ObjectivesThe Government of India launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) to expand access to affordable generics through private retail outlets named as Jan Aushadhi Kendras (JAKs). This study examines the association of PMBJP with out-of-pocket expenditure (OOPE), catastrophic health expenditure (CHE) and impoverishment rate (IR) attributable to medicines.DesignA cross-sectional observational study was conducted across nine Indian states in 2022–2023.SettingOutpatient (OPD) and inpatient (IPD) departments of secondary and tertiary government hospitals, private pharmacies and JAKs in 18 districts of IndiaParticipantsA total of 10 336 patients were recruited from OPD (n=2881) and IPD (n=1009) departments of government hospitals as well as pharmacy settings (n=6446). Data on sociodemographics, disease severity, number of generic prescriptions, source of acquiring medicines and medicine-related OOPE were collected through semistructured interviews and periodic follow-ups.Primary and secondary outcomesPrimary outcomes included mean OOPE on medicines, incidence of CHE (≥40% of non-food consumption expenditure on medicines), IR among JAK and non-JAK users were the primary outcomes of the study. Secondary outcomes comprised awareness of JAKs, generic prescribing rates in hospitals and the factors associated with OOPE, CHE and IR.ResultsPatients procuring medicines exclusively from JAKs reported the lower mean OOPE (OPD: ₹172; IPD: ₹275; pharmacy: ₹307), compared with significantly higher spending at private pharmacies (OPD: ₹1085; IPD: ₹3165; pharmacy: ₹1031). After adjusting for covariates, OOPE among exclusive JAK users was significantly lower relative to private pharmacy users by 60.6%–89.3%. Furthermore, matched analysis confirmed 42% lower expenses, compared with private pharmacies. The likelihood of CHE was also significantly greater among private pharmacy users. However, utilisation of JAKs remained limited, mainly due to low awareness, perceived stock shortages and low rates of generic prescribing.ConclusionPMBJP is associated with significant reduction in OOPE and financial hardship, positioning it as an effective cost-containment intervention within India’s universal health coverage framework. Strengthening supply chains, promoting generic prescribing and integrating JAKs with public facilities would further maximise its impact.
